December 18, 2013 10:16 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Wednesday, JMP Securities analyst J.T. Haresco initiated coverage on
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NASDAQ: FMI) with a Market Outperform rating and $33.00 price target.In the report, JMP Securities noted, “We are initiating coverage on Foundation Medicine (FMI) with a Market Outperform rating and $33 price target. The company's FoundationOne test is currently the only commercially available pan-cancer panel that delivers concise, comprehensive, actionable, and patient-specific treatment options. The company has a clear first-mover advantage, and while there is uncertainty around the timing of reimbursement and the sustainability of pricing, we believe the company can maintain its position even in the face of increased competition in the space. Our $33 price target implies a 2015 EV/Sales multiple of 11.8x, representing an 18% premium relative to its same peer group. FMI is also being valued as a biotech company and we think it reasonable that our price target reflects an enterprise value (using projected levels of debt and cash) that is ~13x our revenue estimate for the twelve months ended September 2015, a multiple that is in line with the peer group median.”Foundation Medicine closed on Tuesday at $23.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.